DC-CIK细胞治疗晚期卵巢癌的临床疗效  

Clinical efficacy of patients with advanced ovarian cancer treated with DC-CIK cytotherapy

作　　者：郑劼[1] 江龙委[1] 姚露[1] 陆晓[1] 杨爱珍[1] 艾月琴[1] 张燕[1] 张闯[1] 黄伟谦[1] 高艳荣[1] 赵华[1] 胡建华[1] 贾绍昌[1] ZHENG Jie JIANG Longwei YAO Lu LU Xiao YANG Aizhe AI Yueqin ZHANG Yan ZHANG Chuang HUANG Weiqian GAO Yanrong ZHAO Hua HU Jianhua J(Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China)

机构地区：[1]解放军第81医院肿瘤生物治疗科,江苏南京210001

出　　处：《中国肿瘤生物治疗杂志》2016年第5期682-687,共6页Chinese Journal of Cancer Biotherapy

基　　金：南京军区医学科技创新项目资助(No.14MS052)~~

摘　　要：目的:评价自体DC-CIK细胞治疗晚期卵巢癌患者的临床疗效和安全性。方法:采集2011年8月至2016年1月解放军第81医院肿瘤生物治疗科收治的28例Ⅳ期卵巢癌患者的PBMC,经实验室体外诱导培养获得DC和CIK细胞。DC通过卵巢癌细胞(HO-8910)裂解物致敏后与CIK细胞回输至患者体内,观察DC-CIK细胞治疗前后患者临床疗效和安全性。结果:28例晚期卵巢癌患者经DC-CIK细胞免疫治疗后,ORR为7.1%(2/28),DCR为64.3%(18/28);12、36、50个月的累积生存率分别为有75%、53%和42%。经DC-CIK细胞治疗后患者外周血CD3^+CD8^+细胞比例显著升高[(23.35±7.52)%vs(29.49±8.16)%;t=-3.340,P<0.01],CD4^+/CD8^+比例显著下降[(1.61±0.84)%vs(1.21±0.74)%;t=2.785,P<0.05],CD3^+、CD3^+CD4^+、CD3^-CD56^+、CD4^+CD25^+细胞比例及CA125、CA199、TSGF水平均无显著变化(均P>0.05);患者治疗后均无明显不良反应。结论:DC-CIK细胞治疗可改善晚期卵巢癌患者免疫状态,提高其中远期生存率,患者无明显不良反应,安全可行。Objective：To evaluate clinical efficacy and safety of patients with advanced ovarian cancer treated with autogenous DC-CIK cytotherapy.Methods：Peripheral blood mononuclear cells of 28 patients with Ⅳ stage ovarian cancer who hospitalized in the Department of Tumor Biotherapy, the 81th Hospital of PLA during August, 2011 to January, 2016 were collected, from which DC and CIK were obtained with culture in vitro. DC sensitized by lysate of ovarian cancer HO-8910 line cell and CIK were transfused into the patients with ovarian cancer. Before and after the treatment, clinical efficacy and safety of the patients were observed. Results： After 28 patients with advanced ovarian cancer treated by DC-CIK immunotherapy, overall response rate （ORR） and disease control rate （DCR） of the patents were 7.1% （2/28） and 643（18/28） respectively, overall survival （OS） for 12, 36 and 50 months were 75%, 54% and 42% respectively. After treatment of DC-CIK immunotherapy, proportion of CD3＋CD8＋ in peripheral blood of the patients significantly increased compared to before the treatment （／[23.35±7.52／]% vs ／[29.49±8.16／]%; t=-3.340, P〈0.01）, CD4＋/CD8＋ ratio obviously decreased （／[1.61±0.84／]% vs ／[1.21±0.74／]%; t= 2.785, P〈0.05）, proportion of CD3＋, CD3＋CD4＋, CD3-CD56＋ , CD4＋CD25＋ cells and levels of CA125, CA199, TSGF did not significantly change （all P〉0.05）. There not were any obvious adverse reaction in all the patients after the treatment. Conclusion： DC-CIK cytotherapy could be as a safe and feasible theraputic approach which might improve immune status of the patients with advanced ovarian cancer, increase mid long term survival rate of the patients, and any obvious adverse reaction did not found in the patients treated with the immunotherapy.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 晚期卵巢癌 细胞免疫治疗 临床疗效 

分 类 号：R737.31[医药卫生—肿瘤] R730.51[医药卫生—临床医学]